FDA calls out Brainstorm’s ALS stem cell therapy, says data don’t show benefit

March 3, 2021 Auto Bot amyotrophic lateral sclerosis, BioPharma, biopharma nl, FDA, New York, Pharma 0

FDA sign, headquarters

A Brainstorm Cell Therapeutics therapy for Lou Gehrig’s disease failed a pivotal study, but the company points to better results in a subgroup. The FDA took the unusual step of publicly stating that study’s results do not show the stem cell therapy helps patients.